BioCentury | Mar 20, 2006
Company News

Norwood Abbey, Massachusetts Institute of Technology deal

...granted NAL exclusive worldwide rights to a needle-free injection technology. MIT is eligible for royalties. Norwood Abbey Ltd....
BioCentury | Nov 21, 2005
Clinical News

Melanoma cancer vaccine: Phase II started

...GnRH analogue is marketed in the U.S. by TAP Pharmaceutical Products Inc. (Lake Forest, Ill). Norwood Abbey...
BioCentury | Oct 11, 2004
Company News

Norwood Abbey board of directors update

Norwood Abbey Ltd. (ASX:NAL), Melbourne, Australia Business: Drug delivery Appointed: Elizabeth Wyatt, former VP of corporate licensing at Merck & Co. Inc. ; Richard Zahn, former president of Schering-Plough Corp. 's Schering Laboratories unit; and...
BioCentury | Jun 28, 2004
Finance

Ebb & Flow

...the second half. Norwood Immunology plans to begin trading on AIM on June 30. Parent Norwood Abbey...
BioCentury | Jun 25, 2004
Financial News

Norwood prices IPO

...AIM market on June 30. KBC Peel Hunt was the underwriter. Norwood Immunology's parent company, Norwood Abbey Ltd....
BioCentury | Jun 24, 2004
Financial News

Norwood updates IPO

...market on June 30, proposed in April to raise AUS$37 million. Norwood Immunology's parent company, Norwood Abbey...
BioCentury | Apr 5, 2004
Financial News

Norwood to list on AIM

...milestones and royalties. TAP also made a $2 million investment in Norwood Immunology's parent company Norwood Abbey...
BioCentury | Apr 7, 2003
Company News

Norwood Abbey management update

Norwood Abbey Ltd. (ASX:NAL), Melbourne, Australia Business: Drug delivery Hired: Richard Williams as CEO of NAL's Norwood Immunology business, formerly senior partner at Andersen WIR Staff...
Items per page:
1 - 8 of 8
BioCentury | Mar 20, 2006
Company News

Norwood Abbey, Massachusetts Institute of Technology deal

...granted NAL exclusive worldwide rights to a needle-free injection technology. MIT is eligible for royalties. Norwood Abbey Ltd....
BioCentury | Nov 21, 2005
Clinical News

Melanoma cancer vaccine: Phase II started

...GnRH analogue is marketed in the U.S. by TAP Pharmaceutical Products Inc. (Lake Forest, Ill). Norwood Abbey...
BioCentury | Oct 11, 2004
Company News

Norwood Abbey board of directors update

Norwood Abbey Ltd. (ASX:NAL), Melbourne, Australia Business: Drug delivery Appointed: Elizabeth Wyatt, former VP of corporate licensing at Merck & Co. Inc. ; Richard Zahn, former president of Schering-Plough Corp. 's Schering Laboratories unit; and...
BioCentury | Jun 28, 2004
Finance

Ebb & Flow

...the second half. Norwood Immunology plans to begin trading on AIM on June 30. Parent Norwood Abbey...
BioCentury | Jun 25, 2004
Financial News

Norwood prices IPO

...AIM market on June 30. KBC Peel Hunt was the underwriter. Norwood Immunology's parent company, Norwood Abbey Ltd....
BioCentury | Jun 24, 2004
Financial News

Norwood updates IPO

...market on June 30, proposed in April to raise AUS$37 million. Norwood Immunology's parent company, Norwood Abbey...
BioCentury | Apr 5, 2004
Financial News

Norwood to list on AIM

...milestones and royalties. TAP also made a $2 million investment in Norwood Immunology's parent company Norwood Abbey...
BioCentury | Apr 7, 2003
Company News

Norwood Abbey management update

Norwood Abbey Ltd. (ASX:NAL), Melbourne, Australia Business: Drug delivery Hired: Richard Williams as CEO of NAL's Norwood Immunology business, formerly senior partner at Andersen WIR Staff...
Items per page:
1 - 8 of 8